9 reports

  • Pipeline analysis
  • Vendor landscape

Manufactures monoclonal antibody-based therapeutics that treats autoimmune diseases.

  • Diabetes
  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • MONOCLONAL ANTIBODY CONJUGATE TO TARGET ASGPR FOR TYPE I DIABETES - DRUG PROFILE
  • MK-5160 - DRUG PROFILE

GNBAC-## IS A HUMANIZED MONOCLONAL ANTIBODY OF IMMUNOGLOBULIN G## TYPE.

  • Chronic Disease
  • Type 1 Diabetes
  • United States
  • World
  • Company

The monoclonal antibody elicits anti-cancer activity.

  • Targeted Therapy
  • Type 1 Diabetes
  • United States
  • Product Initiative
  • Xencor, Inc.

In line with the strategic focus on diabetes, Adocia terminated the mAbs (using Adocia technologies to improve formulation of third-parties proprietary monoclonal antibodies) and DriveIn®(nanoparticle-based drug delivery technology in oncology) programs, both at a preclinical stage

  • Insulin
  • Type 1 Diabetes
  • United States
  • Company
  • Adocia

Lee' s Pharmaceutical Holdings Ltd, entered into agreement with Shenogen Pharma Group Ltd, to jointly develop and commercialize a combination product that is composed of their respective compounds, ZKAB## (PD-L## monoclonal antibody) and icaritin, for treatment of late stage ca

  • Therapy
  • Type 1 Diabetes
  • World
  • Product Initiative
  • Shenogen Pharma Group
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Endocrine Disease
  • Type 1 Diabetes
  • World
  • Product Initiative
  • PARTNERSHIPS

The company produces a wide range of active pharmaceutical ingredients (APIs), branded formulations; and complex biologics both novels and biosimilars including monoclonal antibodies (MAbs), rh-Insulin and insulin analogs.

  • Diabetes
  • Pharmaceutical
  • Type 1 Diabetes
  • United States
  • Sernova Corp.
  • TYPE 1 DIABETES (JUVENILE DIABETES) - PIPELINE BY MEDY-TOX INC., H2 2016
  • TYPE 1 DIABETES (JUVENILE DIABETES) - DORMANT PROJECTS (CONTD..8), H2 2016

Its product candidates include monoclonal antibodies (mAbs), glycobiology antiviral agents and cell-based therapies.

  • Pharmaceutical
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Company
  • Product Initiative
  • Clinical Trial Profile Snapshots

About XOMA ## XOMA ## is a fully human, high affinity monoclonal antibody fragment that specifically targets the human insulin receptor (INSR).

  • Clinical Trial
  • Drug Development
  • Type 1 Diabetes
  • World
  • Product Initiative